Curative Biotechnology Stock Probability Of Bankruptcy

CUBT Stock  USD 0.01  0.0003  2.22%   
Curative Biotechnology's chance of distress is over 65% at this time. It has high odds to experience some financial crisis in the next few years. Probability of financial unrest prediction helps decision makers evaluate Curative Biotechnology's chance of financial distress in relation to its going-concern outlook and evaluation. All items used in analyzing the odds of distress are taken from the Curative balance sheet, as well as cash flow and income statements available from the company's most recent filings. Check out Curative Biotechnology Piotroski F Score and Curative Biotechnology Altman Z Score analysis.
For more information on how to buy Curative Stock please use our How to Invest in Curative Biotechnology guide.
  
Market Cap is likely to gain to about 13.3 M in 2025. Enterprise Value is likely to gain to about 15.4 M in 2025

Curative Biotechnology Company probability of financial unrest Analysis

Curative Biotechnology's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Probability Of Bankruptcy

 = 

Normalized

Z-Score

More About Probability Of Bankruptcy | All Equity Analysis

Current Curative Biotechnology Probability Of Bankruptcy

    
  Over 78%  
Most of Curative Biotechnology's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Curative Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Curative Biotechnology probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Curative Biotechnology odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Curative Biotechnology financial health.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Curative Biotechnology. If investors know Curative will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Curative Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.01)
Return On Assets
(0.52)
Return On Equity
(3.98)
The market value of Curative Biotechnology is measured differently than its book value, which is the value of Curative that is recorded on the company's balance sheet. Investors also form their own opinion of Curative Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Curative Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Curative Biotechnology's market value can be influenced by many factors that don't directly affect Curative Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Curative Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Curative Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Curative Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Curative Probability Of Bankruptcy Driver Correlations

Understanding the fundamental principles of building solid financial models for Curative Biotechnology is extremely important. It helps to project a fair market value of Curative Stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since Curative Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Curative Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Curative Biotechnology's interrelated accounts and indicators.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
Competition

Based on the latest financial disclosure, Curative Biotechnology has a Probability Of Bankruptcy of 78%. This is 80.18% higher than that of the Biotechnology sector and 42.23% higher than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 95.83% lower than that of the firm.

Curative Probability Of Bankruptcy Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Curative Biotechnology's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Curative Biotechnology could also be used in its relative valuation, which is a method of valuing Curative Biotechnology by comparing valuation metrics of similar companies.
Curative Biotechnology is currently under evaluation in probability of bankruptcy category among its peers.

Curative Biotechnology Main Bankruptcy Drivers

202020212022202320242025 (projected)
Return On Assets(2.05)(2.21)(2.68)(2.23)(2.57)(2.44)
Net Debt399.2K(670.3K)1.0M2.2M2.5M2.7M
Total Current Liabilities665.0K730.3K4.5M5.7M6.6M6.9M
Total Assets2.3M2.4M2.1M2.6M3.0M3.1M
Total Current Assets2.1M753.9K68.7K604.5K695.1K369.0K
Total Cash From Operating Activities(190.1K)(1.6M)(1.5M)(486.6K)(437.9K)(459.8K)

Curative Fundamentals

About Curative Biotechnology Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Curative Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Curative Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Curative Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Curative Stock Analysis

When running Curative Biotechnology's price analysis, check to measure Curative Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curative Biotechnology is operating at the current time. Most of Curative Biotechnology's value examination focuses on studying past and present price action to predict the probability of Curative Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curative Biotechnology's price. Additionally, you may evaluate how the addition of Curative Biotechnology to your portfolios can decrease your overall portfolio volatility.